What the trials measured
Foundayo was tested in the ATTAIN trials. These are the published results — the trials were run with a capsule at 6, 12 and 36 mg, which the FDA label shows as the equivalent 5.5, 9 and 17.2 mg tablet doses. The figures here are totals at week 72 rather than month-by-month figures.
- Who took part:
- 3,127 adults with obesity, or overweight with weight-related conditions, without type 2 diabetes
- How long:
- 72 weeks
- Compared with:
- Placebo
- Average loss, people who kept taking it:
- 7.8% at 5.5 mg, 9.3% at 9 mg, 12.4% at 17.2 mg (placebo 0.9%)
- Average loss, counting everyone who started:
- 7.5% at 5.5 mg, 8.4% at 9 mg, 11.2% at 17.2 mg (placebo 2.1%)
- Lost at least 5%, everyone who started:
- 60.6%, 63.5% and 71.8% (placebo 26.8%)
- Lost at least 10%, everyone who started:
- 33.3%, 40.0% and 54.6% (placebo 12.9%)
- Lost at least 10%, people who kept taking it:
- 35.9%, 45.1% and 59.6% (placebo 8.6%)
- Lost at least 15%, everyone who started:
- 15.1%, 20.3% and 36.0% (placebo 5.9%)
- Who took part:
- 1,613 adults with obesity or overweight and type 2 diabetes
- How long:
- 72 weeks
- Average loss, people who kept taking it:
- 5.5% at 5.5 mg, 7.8% at 9 mg, 10.5% at 17.2 mg (placebo 2.2%)
- Average loss, counting everyone who started:
- 5.1% at 5.5 mg, 7.0% at 9 mg, 9.6% at 17.2 mg (placebo 2.5%)
- Worth knowing:
- Lower than in participants without diabetes, which is the pattern seen across the GLP-1 class
What the averages look like in pounds
Averages from trial data. Individual results vary, but these give you a realistic picture of what to expect.
| Time | % of body weight | 200 lb person | 250 lb person |
|---|---|---|---|
| 72 weeks, 5.5 mg | 7.8% average | ~16 lbs | ~20 lbs |
| 72 weeks, 9 mg | 9.3% average | ~19 lbs | ~23 lbs |
| 72 weeks, 17.2 mg | 12.4% average | ~25 lbs | ~31 lbs |
The four phases of the year
Knowing where you are in the arc helps you manage expectations — and stops you from panicking when the scale stalls.
Starting dose
- The label starts Foundayo at 0.8 mg, the lowest of its six strengths
- You stay on each of the first three doses for at least 30 days
- The label reports weight loss for 5.5, 9 and 17.2 mg only, so this page has no figure for this dose
Stepping up
- The label moves to 2.5 mg, then 5.5 mg, after at least 30 days on each
- In ATTAIN-1, 5.5 mg was the lowest dose with a reported result
- Average loss at week 72 on 5.5 mg was 7.8% for people who kept taking it
Optional higher doses
- Steps to 9, 14.5 or 17.2 mg are optional and based on response and tolerability
- Average week-72 loss was 9.3% on 9 mg and 12.4% on 17.2 mg
- Your prescriber sets the pace
Staying on treatment
- ATTAIN-1 reports its main results at 72 weeks
- No withdrawal trial has been published for Foundayo
- Other GLP-1 drugs show weight regain after stopping, so the same is generally expected here
The first month: managing expectations
Why this page has no month-by-month figures
Foundayo starts at 0.8 mg, and the label has you stay on each of the first three doses for at least 30 days. The first three months are therefore spent on the three lowest strengths.
The label reports weight loss for 5.5, 9 and 17.2 mg, and the results here are totals at week 72. This page has no figure for any single month, so it does not give one.
What happens if you stop
The effect is expected to last only while treatment continues
No withdrawal trial has been published for Foundayo. Other GLP-1 drugs show weight regain after stopping in their withdrawal trials, so the same is generally expected here. Any decision to stop is one to make with your prescriber rather than on your own.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical trial data for Orforglipron
Weight loss figures on this page come from ATTAIN-1 (3,127 adults, 72 weeks, NEJM 2025) and ATTAIN-2 (1,613 adults with type 2 diabetes, 72 weeks, The Lancet 2025). The trials used a capsule at 6, 12 and 36 mg, which the FDA label shows as the equivalent 5.5, 9 and 17.2 mg tablet doses. Pound conversions are calculated from the trial percentages at 200 lb and 250 lb starting weights.
- ATTAIN-1 — Orforglipron: 3,127 adults with obesity or overweight with comorbidities, no type 2 diabetes, 72 weeks. New England Journal of Medicine, 2025. View source ↗
- ATTAIN-2 — Orforglipron: Adults with obesity and type 2 diabetes, 72 weeks. The Lancet, 2025. View source ↗
- Foundayo (orforglipron) prescribing information — Clinical Studies (14) View source ↗
- Eli Lilly Medical Information — Foundayo body weight results in phase 3 studies (ATTAIN-1 and ATTAIN-2, both estimands) View source ↗
- Eli Lilly Medical Information — What dosages of Foundayo (orforglipron) capsules are equivalent to the tablet dosages? View source ↗
Keep reading
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: